SCHEMBL7256258

SCHEMBL7256258

COc1ccc2c(c1)[nH]c1cc(OCCNCC(O)c3ccc(F)c(NS(C)(=O)=O)c3)ccc12

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 18/20 0.57
ADRA1A P35348 10/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7256255 1.00 ADRB3 (0.57) ADRB3ADRA1A
Hydrochloric Acid SCHEMBL7251267 0.99 ADRB3 (0.56) ADRB3ADRA1A
Hydrochloric Acid SCHEMBL7251270 0.99 ADRB3 (0.56) ADRB3ADRA1A
SCHEMBL6911028 0.92 ADRB3 (0.54) ADRB3ADRA1A
SCHEMBL6911031 0.92 ADRB3 (0.54) ADRB3ADRA1A
SCHEMBL6914760 0.92 ADRB3 (0.54) ADRB3ADRA1A
SCHEMBL7257177 0.91 ADRB3 (0.51) ADRB3ADRA1A
Hydrochloric Acid SCHEMBL7109227 0.91 ADRB3 (0.53) ADRB3ADRA1A
Hydrochloric Acid SCHEMBL7108984 0.91 ADRB3 (0.53) ADRB3ADRA1A
Hydrochloric Acid SCHEMBL7109232 0.91 ADRB3 (0.53) ADRB3ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US claimed
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040538-A1 Novel substituted tricyclic compounds CPT1A, CBR1, NR1H3 ADRB3 442/4885ADRA1A 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.